共 127 条
[1]
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]
Miller KD(2017)Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a French prospective multicenter study Ann Surg 266 787-796
[3]
Jemal A(2019)Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma BJS Open 3 85-94
[4]
Delpero JR(2019)Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery Ann Surg Oncol 26 1629-1636
[5]
Jeune F(2019)Outcome of patients with borderline resectable pancreatic cancer in the contemporary era of neoadjuvant chemotherapy J Gastrointest Surg 23 112-121
[6]
Bachellier P(2016)Factors that predict the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy Surgery 160 318-330
[7]
Regenet N(2015)Pathophysiology after pancreaticoduodenectomy World J Gastroenterol 21 5794-5804
[8]
Le Treut YP(2014)Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy J Hepato Biliary Pancreat Sci 21 186-192
[9]
Paye F(2016)Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial J Hepato Biliary Pancreat Sci 23 167-173
[10]
Latchana N(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet 388 248-257